GS-4774的安全性，耐受性和免疫原性，HBV特异性的治疗性疫苗

StephenW

Safety, Tolerability, and Immunogenicity of GS-4774,an HBV-Specific Therapeutic Vaccine, in Healthy Volunteers                                     Reported by Jules Levin AASLD Nov 1-4 2013 Wash DC Anuj Gaggar,1 Claire Coeshott,2 David Apelian,2 Tim Rodell,2 Gong Shen,1 Mani Subramanian,1 John McHutchison1 1Gilead Sciences, Inc., Foster City, CA; 2GlobeImmune, Louisville, CO

                                                                       

齐欢畅2

马克，感谢楼主分享。

StephenW

                                                                                        "Ive been asked to be part of this study for Phase 2. I am scared about the side effects of this. I have been on Barraclude for 4 years and dont know when I will be take off of it."

一个病人从Medhelp已被要求参加第2阶段试验。他恩替卡韦治疗4年.